{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:39:49Z","timestamp":1778769589202,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12936-017-1989-3","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T08:39:31Z","timestamp":1503391171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-3081","authenticated-orcid":false,"given":"Olalekan A.","family":"Uthman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia M.","family":"Graves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hellen","family":"Gelband","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marty","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Garner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"1989_CR1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1128\/CMR.00051-10","volume":"24","author":"T Bousema","year":"2011","unstructured":"Bousema T, Drakeley C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev. 2011;24:377\u2013410.","journal-title":"Clin Microbiol Rev"},{"key":"1989_CR2","first-page":"CD008152","volume":"2","author":"PM Graves","year":"2015","unstructured":"Graves PM, Gelband H, Garner P. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2015;2:CD008152.","journal-title":"Cochrane Database Syst Rev"},{"key":"1989_CR3","doi-asserted-by":"crossref","first-page":"e004664","DOI":"10.1136\/bmjopen-2013-004664","volume":"4","author":"OA Uthman","year":"2014","unstructured":"Uthman OA, Saunders R, Sinclair D, Graves P, Gelband H, Clarke A, et al. Safety of 8-aminoquinolines given to people with G6PD deficiency: protocol for systematic review of prospective studies. BMJ Open. 2014;4:e004664.","journal-title":"BMJ Open"},{"key":"1989_CR4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","volume":"371","author":"MD Cappellini","year":"2008","unstructured":"Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64\u201374.","journal-title":"Lancet"},{"key":"1989_CR5","doi-asserted-by":"crossref","first-page":"e1001339","DOI":"10.1371\/journal.pmed.1001339","volume":"9","author":"RE Howes","year":"2012","unstructured":"Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.","journal-title":"PLoS Med"},{"key":"1989_CR6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/B978-0-12-407826-0.00004-7","volume":"81","author":"RE Howes","year":"2013","unstructured":"Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol. 2013;81:133\u2013201.","journal-title":"Adv Parasitol"},{"key":"1989_CR7","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2010","unstructured":"WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2010.","edition":"2"},{"key":"1989_CR8","unstructured":"WHO. Single dose primaquine as a gametocyte in Plasmodium falciparum malaria. Updated WHO Policy Recommendation (October 2012). Geneva: Global Malaria Programme. World Health Organization; 2012."},{"key":"1989_CR9","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"1989_CR10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1475-2875-13-418","volume":"13","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.","journal-title":"Malar J"},{"key":"1989_CR11","unstructured":"Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization; 2014. \n                        http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241506977\/en\/\n                        \n                    . Accessed 05 July 2017."},{"key":"1989_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1473-3099(12)70198-6","volume":"13","author":"NJ White","year":"2013","unstructured":"White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013;13:175\u201381.","journal-title":"Lancet Infect Dis"},{"key":"1989_CR13","first-page":"601","volume":"67","author":"WHO Working Group","year":"1989","unstructured":"WHO Working Group. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull World Health Organ. 1989;67:601\u201311.","journal-title":"Bull World Health Organ"},{"key":"1989_CR14","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1178849","volume":"326","author":"C Louicharoen","year":"2009","unstructured":"Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, Peerapittayamongkol C, et al. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science. 2009;326:1546\u20139.","journal-title":"Science"},{"key":"1989_CR15","unstructured":"Suggested risk of bias criteria for EPOC reviews. \n                        http:\/\/epoc.cochrane.org\/sites\/epoc.cochrane.org\/files\/uploads\/Suggested%20risk%20of%20bias%20criteria%20for%20EPOC%20reviews.pdf\n                        \n                    . Accessed 14 Mar 2014."},{"key":"1989_CR16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"issue":"Suppl 1","key":"1989_CR17","first-page":"97","volume":"75","author":"JR Zucker","year":"1997","unstructured":"Zucker JR, Perkins BA, Jafari H, Otieno J, Obonyo C, Campbell CC. Clinical signs for the recognition of children with moderate or severe anaemia in western Kenya. Bull World Health Organ. 1997;75(Suppl 1):97\u2013102.","journal-title":"Bull World Health Organ"},{"key":"1989_CR18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1046\/j.1365-3156.2000.00637.x","volume":"5","author":"L Muhe","year":"2000","unstructured":"Muhe L, Oljira B, Degefu H, Jaffar S, Weber MW. Evaluation of clinical pallor in the identification and treatment of children with moderate and severe anaemia. Trop Med Int Health. 2000;5:805\u201310.","journal-title":"Trop Med Int Health"},{"issue":"Supplement 1","key":"1989_CR19","first-page":"1","volume":"94","author":"WHO","year":"2000","unstructured":"WHO. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94(Supplement 1):1\u201310.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1989_CR20","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1365-3156.2007.01960.x","volume":"12","author":"P Ouma","year":"2007","unstructured":"Ouma P, van Eijk AM, Hamel MJ, Parise M, Ayisi JG, Otieno K, et al. Malaria and anaemia among pregnant women at first antenatal clinic visit in Kisumu, western Kenya. Trop Med Int Health. 2007;12:1515\u201323.","journal-title":"Trop Med Int Health"},{"key":"1989_CR21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/trstmh\/trt096","volume":"107","author":"R Reithinger","year":"2013","unstructured":"Reithinger R, Ngondi JM, Graves PM, Hwang J, Getachew A, Jima D. Risk factors for anemia in children under 6\u00a0years of age in Ethiopia: analysis of the data from the cross-sectional Malaria Indicator Survey, 2007. Trans R Soc Trop Med Hyg. 2013;107:769\u201376.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"1989_CR22","doi-asserted-by":"crossref","first-page":"e1023","DOI":"10.1371\/journal.pone.0001023","volume":"2","author":"S Shekalaghe","year":"2007","unstructured":"Shekalaghe S, Drakeley C, Gosling R, Ndaro A, van Meegeren M, Enevold A, et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine\u2013pyrimethamine and artesunate. PLoS ONE. 2007;2:e1023.","journal-title":"PLoS ONE"},{"key":"1989_CR23","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.01135-09","volume":"54","author":"SA Shekalaghe","year":"2010","unstructured":"Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A\u2212) individuals. Antimicrob Agents Chemother. 2010;54:1762\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1989_CR24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3347\/kjp.2006.44.3.221","volume":"44","author":"S Krudsood","year":"2006","unstructured":"Krudsood S, Wilairatana P, Tangpukdee N, Chalermrut K, Srivilairit S, Thanachartwet V, et al. Safety and tolerability of elubaquine (bulaquine, CDRI 80\/53) for treatment of Plasmodium vivax malaria in Thailand. Korean J Parasitol. 2006;44:221\u20138.","journal-title":"Korean J Parasitol"},{"key":"1989_CR25","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"1989_CR26","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"1989_CR27","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1128\/AAC.02889-14","volume":"58","author":"AC Eziefula","year":"2014","unstructured":"Eziefula AC, Pett H, Grignard L, Opus S, Kiggundu M, Kamya MR, et al. Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected African children receiving single-dose primaquine. Antimicrob Agents Chemother. 2014;58:4971\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1989_CR28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12936-016-1341-3","volume":"15","author":"R Mwaiswelo","year":"2016","unstructured":"Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of primaquine in addition to standard artemether\u2013lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J. 2016;15:316.","journal-title":"Malar J"},{"key":"1989_CR29","doi-asserted-by":"crossref","first-page":"e0151898","DOI":"10.1371\/journal.pone.0151898","volume":"11","author":"G Bancone","year":"2016","unstructured":"Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, Gornsawun G, et al. Single low dose primaquine (0.25\u00a0mg\/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS ONE. 2016;11:e0151898.","journal-title":"PLoS ONE"},{"key":"1989_CR30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12916-015-0441-1","volume":"13","author":"S Kheng","year":"2015","unstructured":"Kheng S, Muth S, Taylor WR, Tops N, Kosal K, Sothea K, et al. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med. 2015;13:203.","journal-title":"BMC Med"},{"key":"1989_CR31","doi-asserted-by":"crossref","first-page":"e0154015","DOI":"10.1371\/journal.pone.0154015","volume":"11","author":"B Ley","year":"2016","unstructured":"Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, et al. G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study. PLoS ONE. 2016;11:e0154015.","journal-title":"PLoS ONE"},{"key":"1989_CR32","unstructured":"Rueangweerayut R, Bancone G, Beelen AP, Carter N, Duparc S, Green JA, et al. A phase I study to investigate the haemolytic potential of tafenoquine in healthy subjects with glucose-6-phosphate dehydrogenase deficiency (TAF110027). In: Conference: 61st annual meeting of the American Society of Tropical Medicine and Hygiene, ASTMH 2012 Atlanta, GA, USA."},{"key":"1989_CR33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1473-3099(13)70268-8","volume":"14","author":"AC Eziefula","year":"2014","unstructured":"Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis. 2014;14:130\u20139.","journal-title":"Lancet Infect Dis"},{"key":"1989_CR34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12936-016-1410-7","volume":"15","author":"E Poirot","year":"2016","unstructured":"Poirot E, Soble A, Ntshalintshali N, Mwandemele A, Mkhonta N, Malambe C, et al. Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether\u2013lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. Malar J. 2016;15:384.","journal-title":"Malar J"},{"issue":"Suppl 1","key":"1989_CR35","doi-asserted-by":"crossref","first-page":"P72","DOI":"10.1186\/1475-2875-13-S1-P72","volume":"13","author":"E Poirot","year":"2014","unstructured":"Poirot E, Stergachis A, ter Kuile F, Guerin PJ, Chen I, Gosling R. Pharmacovigilance for single low-dose primaquine: a practical approach. Malar J. 2014;13(Suppl 1):P72.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-017-1989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T08:39:46Z","timestamp":1503391186000},"score":1,"resource":{"primary":{"URL":"http:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-017-1989-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1186\/s12936-017-1989-3","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]},"article-number":"346"}}